Xenon Pharmaceuticals Inc.

Novartis Ag

Novartis Pharma Gmbh

Duanjie Hou

Shaoyi Sun

Rajender Kamboj

Vishnumurthy Kodumuru

Zaihui Zhang

Jianmin Fu

Serguei Sviridov

Vandna Raina

Nagasree Chakka

Shifeng Liu

Sultan Chowdhury

Mikhail A Chafeev

Natalia Pokrovskaia

Mehran Seid Bagherzadeh

Natalie Alysia Dales

Robert Fraser

Jian-Min Fu

Melwyn A Abreo

Mark W Holladay

Jianyu Sun

Michael D Winther

Heinz W Gschwend

Chi Tu

Wenbao Li

Tom Hsieh

Julia Fonarev

Sengen Sun

Qi Jia

Daniel F Harvey

Kashinath Sadalapure

Mehran Bagherzadeh

Mikhail Kondratenko

Cindy J Hudson

Shifeng Lui

Mikhail A Kondratenko

Jian-min Fu

Mikhail Chafev

Rajender K Kamboj

Kashinath Sadalupure

Sun Shaoyi

Michael Winther

Heinz Gschwend

The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

Organic compounds

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I), where V, W, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. 

Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors

This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R, R, R, R, R, R, R, R, and Rare as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and/or prevention of hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer. 

Use of spiro-oxindole compounds as therapeutic agents

This invention is directed to spiro-oxindole compounds of formula (I): wherein k, j, Q, RR, R, R, R, R, R, R, and Rare as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.

Spiro-oxindole compounds and their uses as therapeutic agents

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, J, K, W, V, R, R, R, R, R, R, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. 

Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors

Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, R, R, R, R, R, R, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Substituted pyridazines as stearoyl-CoA desaturase inhibitors

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): Formula (I) where x, y, G, J, L, M, V, W, R, R, R, R, R, R, R, R, R, R, and Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase

This invention is directed to the use of SCD-1 inhibitors of the formula (I): where x, y, V, W, G, J, L, M, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein, in combination with other drug therapies to treat adverse weight gain. 

Combination therapy

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): 

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (Ia): where x, y, W, V, R, R, R, R, R, R, R, R, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Pyridazine derivatives and their use as therapeutic agents

This invention is directed to spiro-oxindole compounds of formula (I): wherein k, j, Q, R, R, R, R, R, R, R, R, and Rare as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.

Compounds of formula (Ia): where x, y, G, L, M, W, R, R, R, R, R, R, R, R, Rand Rare defined herein, are disclosed, as well as pharmaceutical compositions comprising the compounds. These compounds and pharmaceutical compositions are useful in treating SCD-mediated diseases or conditions.

Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors

Growing community of inventors

Burnaby, Canada

Duanjie Hou